<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03740945</url>
  </required_header>
  <id_info>
    <org_study_id>ERC-260</org_study_id>
    <nct_id>NCT03740945</nct_id>
  </id_info>
  <brief_title>Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer</brief_title>
  <official_title>Effect of Intravaginal Prasterone (DHEA) on Moderate to Severe Symptoms of Vulvovaginal Atrophy Due to Menopause, in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer - (Placebo-Controlled, Double Blind and Randomized Phase III Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EndoCeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AMAG Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>EndoCeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the efficacy of intravaginal prasterone (DHEA) on
      moderate to severe (MS) and most bothersome symptoms (MBS) of vulvovaginal atrophy (VVA) due
      to natural, surgical or treatment-induced menopause, in women with breast cancer who are
      under treatment with an aromatase inhibitor.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Business decision to not perform this study.
  </why_stopped>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline to Week 12 in the Percentage of Superficial Cells</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline to Week 12 in the Percentage of Parabasal Cells</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline to Week 12 in Vaginal pH</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline to Week 12 in Moderate/Severe VVA symptom being Most Bothersome (MBS)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 12 in Moderate/Severe VVA symptom (not most bothersome)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 12 on arousal/lubrication domain of Female Sexual Function Index (FSFI) questionnaire</measure>
    <time_frame>12 weeks</time_frame>
    <description>Individual domain score will be obtained by adding the scores of the individual questions that comprise the domain and multiplying the sum by the domain factor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 12 on subjective arousal domain of FSFI</measure>
    <time_frame>12 weeks</time_frame>
    <description>Individual domain score will be obtained by adding the scores of the individual questions that comprise the domain and multiplying the sum by the domain factor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 12 on desire domain of FSFI</measure>
    <time_frame>12 weeks</time_frame>
    <description>Individual domain score will be obtained by adding the scores of the individual questions that comprise the domain and multiplying the sum by the domain factor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 12 on satisfaction domain of FSFI</measure>
    <time_frame>12 weeks</time_frame>
    <description>Individual domain score will be obtained by adding the scores of the individual questions that comprise the domain and multiplying the sum by the domain factor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 12 on orgasm domain of FSFI</measure>
    <time_frame>12 weeks</time_frame>
    <description>Individual domain score will be obtained by adding the scores of the individual questions that comprise the domain and multiplying the sum by the domain factor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Secretions</measure>
    <time_frame>12 weeks</time_frame>
    <description>Vaginal parameter evaluated at gynecological examination by the physician/gynecologist will be graded as corresponding to none, mild, moderate, or severe atrophy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Surface Thickness</measure>
    <time_frame>12 weeks</time_frame>
    <description>Vaginal parameter evaluated at gynecological examination by the physician/gynecologist will be graded as corresponding to none, mild, moderate, or severe atrophy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Integrity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Vaginal parameter evaluated at gynecological examination by the physician/gynecologist will be graded as corresponding to none, mild, moderate, or severe atrophy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Color</measure>
    <time_frame>12 weeks</time_frame>
    <description>Vaginal parameter evaluated at gynecological examination by the physician/gynecologist will be graded as corresponding to none, mild, moderate, or severe atrophy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Vaginal Atrophy in Breast Cancer Patients</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo vaginal ovule daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prasterone (DHEA) vaginal ovule daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Daily administration of one placebo vaginal ovule at bedtime</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasterone (DHEA)</intervention_name>
    <description>Daily administration of one prasterone vaginal ovule at bedtime</description>
    <arm_group_label>Prasterone</arm_group_label>
    <other_name>Intrarosa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Main criteria:

          1. Natural, surgically- or treatment-induced postmenopausal women (non hysterectomized or
             hysterectomized) with breast cancer (stage 1 or 2) who is currently under treatment
             with an aromatase inhibitor and will remain on that treatment for the duration of the
             study.

          2. Women between 30 and 80 years of age

          3. Women having ≤5% of superficial cells on vaginal smear at baseline

          4. Women having a vaginal pH above 5 at baseline

          5. Women who have self-identified moderate or severe symptom(s) of vaginal atrophy

        Exclusion Criteria:

        Main criteria:

          1. Clinically significant metabolic or endocrine disease (including diabetes mellitus)
             not controlled by medication

          2. The administration of any investigational drug within 30 days of screening visit
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claude Labrie, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Endoceutics, Inc., Quebec, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David F Archer, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jones Institute, Norfolk VA 23507</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheryl Kingsberg, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>MacDonald Women's Hospital, Cleveland, OH 44106 USA</affiliation>
  </overall_official>
  <results_reference>
    <citation>Ke Y, Labrie F, Gonthier R, Simard JN, Bergeron D, Martel C, Vaillancourt M, Montesino M, Lavoie L, Archer DF, Balser J, Moyneur E; other participating Members of the Prasterone Clinical Research Group. Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration. J Steroid Biochem Mol Biol. 2015 Nov;154:186-96. doi: 10.1016/j.jsbmb.2015.08.016. Epub 2015 Aug 17.</citation>
    <PMID>26291918</PMID>
  </results_reference>
  <results_reference>
    <citation>Labrie F, Derogatis L, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É; Members of the VVA Prasterone Research Group. Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. J Sex Med. 2015 Dec;12(12):2401-12. doi: 10.1111/jsm.13045. Epub 2015 Nov 23.</citation>
    <PMID>26597311</PMID>
  </results_reference>
  <results_reference>
    <citation>Labrie F, Montesino M, Archer DF, Lavoie L, Beauregard A, Côté I, Martel C, Vaillancourt M, Balser J, Moyneur E; other participating Members of the Prasterone Clinical Research Group. Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner. Climacteric. 2015;18(6):817-25. doi: 10.3109/13697137.2015.1077508. Epub 2015 Oct 30.</citation>
    <PMID>26517756</PMID>
  </results_reference>
  <results_reference>
    <citation>Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É; VVA Prasterone Research Group. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016 Mar;23(3):243-56. doi: 10.1097/GME.0000000000000571.</citation>
    <PMID>26731686</PMID>
  </results_reference>
  <results_reference>
    <citation>Martel C, Labrie F, Archer DF, Ke Y, Gonthier R, Simard JN, Lavoie L, Vaillancourt M, Montesino M, Balser J, Moyneur É; other participating members of the Prasterone Clinical Research Group. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. J Steroid Biochem Mol Biol. 2016 May;159:142-53. doi: 10.1016/j.jsbmb.2016.03.016. Epub 2016 Mar 10.</citation>
    <PMID>26972555</PMID>
  </results_reference>
  <results_reference>
    <citation>Montesino M, Labrie F, Archer DF, Zerhouni J, Côté I, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Moyneur E, Balser J. Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator. Gynecol Endocrinol. 2016;32(3):240-5. doi: 10.3109/09513590.2015.1110140. Epub 2016 Jan 6.</citation>
    <PMID>26634942</PMID>
  </results_reference>
  <results_reference>
    <citation>Archer DF, Labrie F, Bouchard C, Portman DJ, Koltun W, Cusan L, Labrie C, Côté I, Lavoie L, Martel C, Balser J; VVA Prasterone Group. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause. 2015 Sep;22(9):950-63. doi: 10.1097/GME.0000000000000428.</citation>
    <PMID>25734980</PMID>
  </results_reference>
  <results_reference>
    <citation>Labrie F, Archer DF, Martel C, Vaillancourt M, Montesino M. Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause. Menopause. 2017 Nov;24(11):1246-1256. doi: 10.1097/GME.0000000000000910.</citation>
    <PMID>28640161</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 7, 2018</study_first_submitted>
  <study_first_submitted_qc>November 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <last_update_submitted>November 15, 2019</last_update_submitted>
  <last_update_submitted_qc>November 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vulvovaginal atrophy (VVA)</keyword>
  <keyword>Vaginal atrophy</keyword>
  <keyword>Atrophic vaginitis</keyword>
  <keyword>Prasterone</keyword>
  <keyword>DHEA</keyword>
  <keyword>Intrarosa</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Aromatase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

